Drugs / PENTAXIM™
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials | ||||||
| Phase 3 | NCT01214889 | Sep 2010 → Nov 2011 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00259337 | Feb 2006 → Apr 2008 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00254969 | Oct 2005 → May 2008 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT01491087 | Dec 2011 → Jul 2012 | diphtheria, pertussis, poliomyelitis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT00255021 | Dec 2005 → Sep 2007 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00254917 | Oct 2003 → Feb 2006 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06184542 Comparator | Dec 2023 → Dec 2024 overdue | diphtheria, pertussis, tetanus | Institute of Medical Biology, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pentaxim | “A DTaP-IPV//PRP~T vaccine (Pentaxim, a Sanofi Pasteur AcXim family vaccine) was given to 182 healthy children” PMID 22273029 ↗ Nov 20116“All infants included in the study will receive a booster dose of PENTAXIM™ vaccine at 18-19 months of age.” NCT00254917 ↗ “Aventis Pasteur's DTacP-IPV// PRP\~T combined vaccine (Pentavac™ or Pentaxim™)” NCT00259337 ↗ “Sanofi Pasteur's DTacP-IPV// PRP\~T combined vaccine (Pentavac™ or Pentaxim™)” NCT00255021 ↗ |
| Known as | Pentavac | “Aventis Pasteur's DTacP-IPV// PRP~T combined vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vaccination” NCT00254969 ↗3“Aventis Pasteur's DTacP-IPV// PRP\~T combined vaccine (Pentavac™ or Pentaxim™)” NCT00259337 ↗ “Sanofi Pasteur's DTacP-IPV// PRP\~T combined vaccine (Pentavac™ or Pentaxim™)” NCT00255021 ↗ “Aventis Pasteur's DTacP-IPV//PRP\~T combined vaccine (PENTAVAC™/PENTAXIM)” NCT00254917 ↗ |
| Modality | Vaccine | “Aventis Pasteur's DTacP-IPV//PRP\~T combined vaccine (PENTAVAC™/PENTAXIM)” NCT00254917 ↗ |
| Route | Intramuscular | “0.5 mL, IM” NCT00254917 ↗ |